EUVIMEDEUVIMED entdecken
Open Access

MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors

Carlos Huesa-Berral iD, Julia D Withrow iD, Robert J Dawson iD, Chris Beekman iD, Wesley E Bolch iD, Harald Paganetti iD, Eric Wehrenberg-Klee iD, Alejandro Bertolet iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024-05 · 51 (6) · 1506-1515

DOI: 10.1007/s00259-023-06567-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.12.2023. Verfasst von Carlos Huesa-Berral und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. chuesaberral@mgh.harvard.edu. Hauptthemen laut MEDLINE: Liver Neoplasms, Microspheres, Stochastic Processes, Radiometry. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Massachusetts General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Transarterial radioembolization (TARE) procedures treat liver tumors by injecting radioactive microspheres into the hepatic artery. Currently, there is a critical need to optimize TARE towards a personalized dosimetry approach. To this aim, we present a novel microsphere dosimetry (MIDOS) stochastic model to estimate the activity delivered to the tumor(s), normal liver, and lung. METHODS: MIDOS incorporates adult male/female liver computational phantoms with the hepatic arterial, hepatic portal venous, and hepatic venous vascular trees. Tumors can be placed in both models at user discretion. The perfusion of microspheres follows cluster patterns, and a Markov chain approach was applied to microsphere navigation, with the terminal location of microspheres determined to be in either normal hepatic parenchyma, hepatic tumor, or lung. A tumor uptake model was implemented to determine if microspheres get lodged in the tumor, and a probability was included in determining the shunt of microspheres to the lung. A sensitivity analysis of the model parameters was performed, and radiation segmentectomy/lobectomy procedures were simulated over a wide range of activity perfused. Then, the impact of using different microspheres, i.e., SIR-Sphere®, TheraSphere®, and QuiremSphere®, on the tumor-to-normal ratio (TNR), lung shunt fraction (LSF), and mean absorbed dose was analyzed. RESULTS: Highly vascularized tumors translated into increased TNR. Treatment results (TNR and LSF) were significantly more variable for microspheres with high particle load. In our scenarios with 1.5 GBq perfusion, TNR was maximum for TheraSphere® at calibration time in segmentectomy/lobar technique, for SIR-Sphere® at 1-3 days post-calibration, and regarding QuiremSphere® at 3 days post-calibration. CONCLUSION: This novel approach is a decisive step towards developing a personalized dosimetry framework for TARE. MIDOS assists in making clinical decisions in TARE treatment planning by assessing various delivery parameters and simulating different tumor uptakes. MIDOS offers evaluation of treatment outcomes, such as TNR and LSF, and quantitative scenario-specific decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsMicrospheresStochastic ProcessesRadiometryRadiotherapy Planning, Computer-AssistedHumansMaleFemaleModels, BiologicalEmbolization, Therapeutic

Stichwörter der Autor:innen

MicrospheresRadioembolizationSegmentectomyTumor uptakeYttrium-90

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. chuesaberral@mgh.harvard.edu.
  • J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. abertoletreina@mgh.harvard.edu.

ORCID-Profile: Carlos Huesa-Berral, Julia D Withrow, Robert J Dawson, Chris Beekman, Wesley E Bolch, Harald Paganetti, Eric Wehrenberg-Klee, Alejandro Bertolet

Förderung

  • NCI NIH HHS
  • Massachusetts General Hospital

Zitieren

APA

Huesa-Berral, C., Withrow, J. D., Dawson, R. J., Beekman, C., Bolch, W. E., Paganetti, H., Wehrenberg-Klee, E., & Bertolet, A. (2024). MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors. European Journal of Nuclear Medicine and Molecular Imaging, 51(6), 1506-1515. https://doi.org/10.1007/s00259-023-06567-9

Vancouver

Huesa-Berral C, Withrow JD, Dawson RJ, Beekman C, Bolch WE, Paganetti H, et al. MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(6):1506-1515. doi:10.1007/s00259-023-06567-9

BibTeX
@article{HuesaBerral2024,
  author = {Huesa-Berral, Carlos and Withrow, Julia D and Dawson, Robert J and Beekman, Chris and Bolch, Wesley E and Paganetti, Harald and Wehrenberg-Klee, Eric and Bertolet, Alejandro},
  title = {MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {6},
  pages = {1506--1515},
  doi = {10.1007/s00259-023-06567-9}
}
Kostenlos starten →